Comment on

• Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies.

  Harper JC, Armstrong A, Fried RG, Rieder EA, Alexis AF, Salem RJ, Kasujee I, Grada A. Harper JC, et al. J Am Acad Dermatol. 2023 Oct;89(4):832-834. doi: 10.1016/j.jaad.2023.04.075. Epub 2023 Jun 13. J Am Acad Dermatol. 2023. PMID: 37321481 No abstract available.
• Novel 1726 nm laser demonstrates durable therapeutic outcomes and tolerability for moderate-to-severe acne across skin types.

  Alexiades M, Kothare A, Goldberg D, Dover JS. Alexiades M, et al. J Am Acad Dermatol. 2023 Oct;89(4):703-710. doi: 10.1016/j.jaad.2023.05.085. Epub 2023 Jun 15. J Am Acad Dermatol. 2023. PMID: 37328000
• 5-Aminolevulinic acid photodynamic therapy versus minocycline for moderate-to-severe rosacea: A single-center, randomized, evaluator-blind controlled study.

  Yang J, Liu X, Cao Y, Wang P, Zhang H, Chen Q, Yang Y, Zeng Q, Zhang L, Wang X. Yang J, et al. J Am Acad Dermatol. 2023 Oct;89(4):711-718. doi: 10.1016/j.jaad.2023.06.027. Epub 2023 Jun 24. J Am Acad Dermatol. 2023. PMID: 37356626 Clinical Trial.
• Efficacy and safety of microencapsulated benzoyl peroxide and microencapsulated tretinoin for the treatment of acne vulgaris: Results from two phase 3 double-blind, randomized, vehicle-controlled studies.

  Del Rosso J, Sugarman J, Green L, Lain T, Levy-Hacham O, Mizrahi R, Gold LS. Del Rosso J, et al. J Am Acad Dermatol. 2023 Oct;89(4):719-727. doi: 10.1016/j.jaad.2023.05.093. Epub 2023 Jun 24. J Am Acad Dermatol. 2023. PMID: 37356627 Clinical Trial.